妇科肿瘤学家对II-IV期卵巢癌患者辅助化疗照护的影响
该研究基于2010-2012年爱荷华、堪萨斯和密苏里州诊断为II-IV期及未知分期卵巢癌患者的基于人群的回顾性队列,评估妇科肿瘤学家作为推荐辅助化疗的外科医生和作为辅助化疗提供者的影响,并考虑城乡差异。结果显示妇科肿瘤学家外科医生与辅助化疗启动几率增加相关(OR 2.18),且农村患者较少有妇科肿瘤学家化疗提供者(OR 0.52);妇科肿瘤学家作为化疗提供者与手术至化疗时间缩短(农村6天;城市8天)和化疗距离增加(农村22英里;城市11英里)相关。结论指出妇科肿瘤学家外科医生可能影响辅助化疗启动,作为化疗提供者与一些照护获益和障碍相关,需在其他人群中进一步研究。
要点
- 妇科肿瘤学家外科医生与辅助化疗启动几率增加相关(OR 2.18,95%CI 1.10-4.33)。
- 农村患者较少有妇科肿瘤学家作为化疗提供者(OR 0.52,95%CI 0.30-0.91)。
- 妇科肿瘤学家作为化疗提供者与手术至化疗时间缩短和化疗距离增加相关。
核心结论
- 妇科肿瘤学家外科医生可能影响辅助化疗启动;妇科肿瘤学家作为辅助化疗提供者与一些照护获益(如手术至化疗时间缩短)和障碍(如出行距离增加)相关,包括城乡差异,需在其他人群中进一步研究。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2010-2012年在爱荷华、堪萨斯和密苏里州诊断为II-IV期及未知分期卵巢癌患者,医疗记录于2017-2018年摘录,使用多变量调整逻辑回归和Cox比例风险模型。
主要发现
- 妇科肿瘤学家外科医生(相较于其他类型外科医生)与辅助化疗启动几率增加相关(调整OR 2.18;95%CI 1.10-4.33),且与有妇科肿瘤学家作为辅助化疗提供者相关(OR 10.0;95%CI 4.58-21.8)。
- 独立于外科医生类型,农村患者较少有妇科肿瘤学家作为化疗提供者(OR 0.52;95%CI 0.30-0.91)。
- 妇科肿瘤学家作为辅助化疗提供者(相较于其他提供者)与手术至化疗时间缩短相关(农村:6天;城市:8天),与化疗距离增加相关(农村:22英里;城市:11英里)。
- 农村女性(相较于城市)在化疗提供者为妇科肿瘤学家时出行距离远38英里,在非妇科肿瘤学家时远27英里。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aim to evaluate the impact gynecologic oncologists have on ovarian cancer adjuvant chemotherapy care from their role as surgeons recommending adjuvant chemotherapy care and their role as adjuvant chemotherapy providers while considering rural-urban differences. METHODS: Multivariable adjusted logistic regressions and Cox proportional hazards models were developed using a population-based, retrospective cohort of stage II-IV and unknown stage ovarian cancer patients diagnosed in Iowa, Kansas, and Missouri in 2010-2012 whose medical records were abstracted in 2017-2018. RESULTS: Gynecologic oncologist surgeons (versus other type of surgeon) were associated with increased odds of adjuvant chemotherapy initiation (adjusted odds ratio (OR) 2.18; 95% confidence interval (CI) 1.10-4.33) and having a gynecologic oncologist adjuvant chemotherapy provider (OR 10.0; 95% CI 4.58-21.8). Independent of type of surgeon, rural patients were less likely to have a gynecologic oncologist chemotherapy provider (OR 0.52; 95% CI 0.30-0.91). Gynecologic oncologist adjuvant chemotherapy providers (versus other providers) were associated with decreased surgery-to-chemotherapy time (rural: 6 days; urban: 8 days) and increased distance to chemotherapy (rural: 22 miles; urban: 11 miles). Rural women (versus urban) traveled 38 miles farther when their chemotherapy provider was a gynecologic oncologist and 27 miles farther when it was not. CONCLUSION: Gynecologic oncologist surgeons may impact adjuvant chemotherapy initiation. Gynecologic oncologists serving as adjuvant chemotherapy providers were associated with some care benefits, such as reduced time from surgery-to-chemotherapy, and some care barriers, such as travel distance. The barriers and benefits of having a gynecologic oncologist involved in adjuvant chemotherapy care, including rural-urban differences, warrant further research in other populations.
引用
- Weeks KS, Lynch CF, West M, et al. Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients. Gynecol Oncol. 2021. PMID: 34776243. doi:10.1016/j.ygyno.2021.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。